Abbott’s continuous glucose monitoring (CGM) device, the FreeStyle Libre, has been integrated with Glooko’s digital platform for diabetes management.
The integration is available for individuals with type 1 and type 2 diabetes and healthcare systems across the US through Glooko’s electronic health record (EHR) integration solutions.
Go deeper with GlobalData
Approximately 4.5 million FreeStyle Libre users can now connect data from the CGM device with Glooko’s platform, enabling them to monitor and gain additional insights into health metrics such as diet, exercise, and factors in relation to their diabetes such as insulin usage.
Glooko stated that the integration would in turn give healthcare providers a “more complete” representation of their patient’s diabetes and help inform their approach towards streamlining daily care and enhancing clinical decision-making for individuals.
The integration of Abbott’s CGM adds to Glooko’s existing roster of over 200 integrated devices including CGMs, fitness trackers, and insulin pumps.
The company said it expects the latest integration to significantly expand its US presence and further its ambition towards becoming the leading diabetes management platform provider.
Glooko CEO Mike Alvarez commented: “With this integration, Glooko continues to enhance its interoperability capabilities, providing healthcare systems with the data they need to make more informed decisions and improve patient outcomes.”
California-based Glooko recently completed a $100m Series F financing round in late 2024, bringing its total funding to around $325m since 2012. Founded in 2010, the first iteration of Glooko’s platform gained US Food and Drug Administration (FDA) clearance in December 2012.
Other platforms for diabetes management available in the US include variants from mySugr, Livongo, and Sensulin. Last year, Insulcloud gained FDA clearance for Insulclock CAP, a smart monitoring device for diabetes management, and is now also making plans to establish a presence in what has become a relatively crowded US market.
Diabetes cases in the US have been on the rise over the past few decades, with estimates putting the condition’s incidence rate at around 38.4 million in 2021 versus 15.2 million in the 2000s.
Beyond the US market, Glooko and Danish digital therapeutics company Hedia launched their combined diabetes care technology provision in the UK earlier this year to enhance support for individuals who require bolus insulin dosing support in their daily management. Hedia Diabetes Assistant allows individuals using Glooko’s platform to gain personalised support in calculating insulin doses.
